Phathom Pharmaceuticals, Inc.

PHAT · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$29,973-$75,810-$94,316-$74,451
Dep. & Amort.$156$172$177$193
Deferred Tax$0$0$0$0
Stock-Based Comp.$9,297$8,272$5,540$6,687
Change in WC-$1,557-$5,951-$8,914-$9,036
Other Non-Cash$7,962$10,588$12,583$13,151
Operating Cash Flow-$14,115-$62,729-$84,930-$63,456
Investing Activities
PP&E Inv.-$27-$97-$18-$5
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$27-$97-$18-$5
Financing Activities
Debt Repay.$0$0$0$24,750
Stock Issued$293$80$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$564$0$0$1,296
Financing Cash Flow-$271$80$0$26,046
Forex Effect$0$0$0$0
Net Chg. in Cash-$14,413-$62,746-$84,948-$37,415
Supplemental Information
Beg. Cash$152,431$215,177$300,125$337,540
End Cash$138,018$152,431$215,177$300,125
Free Cash Flow-$14,115-$62,729-$84,948-$63,461
Phathom Pharmaceuticals, Inc. (PHAT) Financial Statements & Key Stats | AlphaPilot